Type 2 diabetes mellitus (T2DM) patients have a higher cardiovascular (CV) occurrence and renal morbidity and mortality, highlighting the need for new reno-CV protection strategies. Recently, new-age antidiabetic drugs; the sodium-glucose co-transporter 2 (SGLT2)-inhibitors, have established cardioprotective and renoprotective effects.1 The EMPA-REG OUTCOME trial showed positive results for the use of empagliflozin, an SGLT2-inhibitor, demonstrating CV outcome benefits in T2DM patients with and without known CV diseases or history of heart failure.2 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 8th February 2021 from 06:00 PM IST onwards. In this webinar, the expert panel (Dr. Melanie Davies, and Dr.
V. Mohan) will share their opinion on the role of SGLT2-inhibitors in cardio-renal metabolic risk management in T2DM. We…